(0.21%) 5 142.25 points
(0.18%) 38 509 points
(0.29%) 17 897 points
(-1.01%) $83.00
(1.66%) $1.955
(-0.17%) $2 343.20
(0.91%) $27.50
(0.27%) $924.60
(-0.20%) $0.933
(-0.18%) $11.00
(-0.26%) $0.798
(1.21%) $92.99
@ $24.99
发出时间: 14 Feb 2024 @ 04:43
回报率: -67.59%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 0.73 %
Live Chart Being Loaded With Signals
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases...
Stats | |
---|---|
今日成交量 | 294 633 |
平均成交量 | 1.35M |
市值 | 281.86M |
EPS | $0 ( 2024-03-12 ) |
下一个收益日期 | ( $-0.780 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.66 |
ATR14 | $0.0110 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Robbins Wendye | Buy | 6 925 | Stock Option (right to buy) |
2024-03-28 | Gray Mary Ann | Buy | 8 574 | Stock Option (right to buy) |
2024-03-28 | Rieflin William Jl | Buy | 11 871 | Stock Option (right to buy) |
2024-01-31 | Ho William | Buy | 75 000 | Employee Stock Option (right to buy) |
2024-01-31 | Young Rodney Kb | Buy | 90 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
94.04 |
Last 100 transactions |
Buy: 3 742 359 | Sell: 63 895 |
音量 相关性
Rapt Therapeutics Inc 相关性 - 货币/商品
Rapt Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-3.55M (0.00 %) |
EPS: | $-3.05 |
FY | 2023 |
营收: | $0 |
毛利润: | $-3.55M (0.00 %) |
EPS: | $-3.05 |
FY | 2022 |
营收: | $1.53M |
毛利润: | $-1.28M (-83.82 %) |
EPS: | $-2.52 |
FY | 2021 |
营收: | $3.81M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.53 |
Financial Reports:
No articles found.
Rapt Therapeutics Inc
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。